Crystalline Forms of Compound I for Scalable Enantiomeric Purity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing Compound (I) are inefficient due to chromatographic separations not suitable for large-scale manufacturing and presence of trace impurities, necessitating the development of novel crystalline forms with improved stability and purity for treating mast cell disorders associated with mutant KIT and PDGFRA alterations.
Innovation Solution
Development of novel crystalline forms of Compound (I), including Forms A, B, C, O, T, and H, which are substantially pure and stable, suitable for large-scale manufacturing and pharmaceutical use, along with methods for preparing these forms to ensure high purity and efficacy as KIT and PDGFRα inhibitors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If chromatographic separations are used to produce Compound (I), then enantiomeric purity is improved, but manufacturing scalability and efficiency deteriorate
Solution Approach 1:
The patent extracts and removes the problematic chromatographic separation step from the manufacturing process. Instead of using chromatography to achieve enantiomeric purity, the invention employs asymmetric synthesis methods that directly produce the desired (S)-enantiomer with high purity, eliminating the need for subsequent separation operations and enabling scalable manufacturing.
Solution Approach 2:
The patent changes the fundamental parameter of the synthesis approach from racemic synthesis followed by separation to asymmetric synthesis. This parameter change in the reaction conditions, catalysts, or reagents used enables direct production of the pure (S)-enantiomer, resolving the contradiction between achieving high purity and maintaining manufacturing efficiency.
2Ease of manufacture
If conventional synthesis methods are used to produce Compound (I), then production simplicity is improved, but product purity deteriorates due to trace impurities
Solution Approach 1:
The patent applies preliminary action by incorporating purification steps early in the synthesis pathway. The crystallization process is designed to occur at strategic points before final product formation, preventing impurity accumulation and ensuring high purity without requiring complex post-synthesis purification operations.
Solution Approach 2:
The patent employs composite crystallization systems that combine multiple purification mechanisms. By using specific solvent combinations, temperature gradients, and crystallization conditions together, the process achieves both simplicity and high purity, as the composite approach handles multiple impurity types simultaneously through a single integrated process.
3Reliability
If high doses of Compound (I) are administered, then treatment efficacy is improved, but side effects and safety concerns worsen
Solution Approach 1:
The patent applies partial action by administering lower doses of the pure (S)-enantiomer compared to what would be required if racemic mixtures were used. Since the synthesis produces only the active (S)-enantiomer without the inactive or potentially harmful (R)-enantiomer, lower doses achieve the same therapeutic effect, reducing side effects while maintaining efficacy.
Data Source
AI summary
Crystalline Forms of Compound (I):pharmaceutically acceptable salts thereof and solvates of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating disorders and conditions associated with oncogenic KIT and PDGFRA alterations using the same, and methods for making Compound (I) and crystalline forms thereof are also disclosed.